Study of SRF388 in Patients With Advanced Solid Tumors


Study Number
777920
Phase
I
Age Group
Adult
Purpose

This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of SRF388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.

Full Title

A Phase 1 Study of SRF388 in Patients with Advanced Solid tumors

ClinicalTrials.Gov ID
NCT04374877

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.